Welcome to our dedicated page for Biolife Solutions news (Ticker: BLFS), a resource for investors and traders seeking the latest updates and insights on Biolife Solutions stock.
BioLife Solutions, Inc. (NASDAQ: BLFS) is a developer and supplier of cell processing tools and services and bioproduction products and services for the cell and gene therapy (CGT) and broader biopharma markets. News about BLFS often centers on how its biopreservation media, CellSeal vials, hPL products, and related cell processing tools are used in clinical trials and commercial CGT therapies, as well as on portfolio changes and strategic transactions.
Investors and industry followers can use this page to track BioLife’s announcements on quarterly and annual financial results, including updates on Cell Processing revenue and the performance of its biopreservation media franchise. The company regularly reports on the contribution of customers with approved therapies, the extent of clinical trial adoption in the United States, and its use of GAAP and non-GAAP measures such as adjusted gross margin and adjusted EBITDA.
BioLife’s news flow also includes updates on portfolio streamlining and strategic moves, such as the divestiture of its evo cold chain logistics subsidiary and earlier sales of Global Cooling, SciSafe, and Custom Biogenic Systems, as well as acquisitions and investments like the PanTHERA CryoSolutions IRI cryopreservation technology and the strategic investment in Pluristyx. These items illustrate how the company is focusing on its core cell processing business while adding scientific capabilities and adjacencies.
In addition, BioLife issues press releases on corporate developments such as the opening of the Aby J. Mathew Center for Biopreservation Excellence in Bothell, Washington, and participation in healthcare and small- and mid-cap investor conferences. For readers following the CGT supply chain, this news page provides a centralized view of BioLife’s operational updates, clinical adoption metrics, strategic transactions, and investor communications over time.
BioLife Solutions (Nasdaq: BLFS) reported preliminary unaudited Q4 2025 revenue from continuing operations of $24.8M, up 20% from $20.7M in Q4 2024. Full-year 2025 preliminary unaudited revenue from continuing operations was $96.2M, up 29% from $74.6M in 2024 and slightly above the raised guidance high end of $96.0M (adjusted for the evo sale). Results exclude discontinued businesses and reflect a $1.3M biopreservation media shipment accelerated into Q3 at a customer's request. The company noted results are preliminary and unaudited and will finalize full 2025 financials when reporting complete results in February 2026.
BioLife Solutions (NASDAQ: BLFS) opened the Aby J. Mathew Center for Biopreservation Excellence at its expanded Bothell headquarters on November 20, 2025.
The 4,500 square foot facility combines state-of-the-art conference and laboratory space to showcase BioLife's cell processing product portfolio, provide customized training and customer workshops, support internal research, and generate applications data for current and pipeline products.
The Center will also support development of next-generation cryopreservation products that incorporate the company's proprietary ice recrystallization inhibitor (IRI) technology acquired earlier in 2025, and serve as a hub for industry collaboration and biopreservation best practices.
BioLife Solutions (NASDAQ: BLFS) announced that management will participate in multiple investor conferences in November and December 2025, including Raymond James Napa Small Cap Symposium on Nov 17, 2025, Stephens Annual Investment Conference on Nov 18–20, 2025, Jefferies Global Healthcare Conference on Nov 17–20, 2025, Furey Research Partners Hidden Gems Conference on Nov 24–25, 2025, Wolfe Research Small & Mid-Cap Conference on Dec 2–3, 2025, and Northland Growth Conference on Dec 16, 2025.
The company said its refreshed investor presentation is now available on the Investor Relations section of the company website.
BioLife Solutions (Nasdaq: BLFS) reported Q3 2025 results showing continued growth in its core cell processing business. Cell Processing revenue rose 33% YoY to $25.4M, total revenue was $28.1M (up 31% YoY), and adjusted EBITDA was $7.8M (28% of revenue). GAAP net income for Q3 was $0.6M. Management raised 2025 Cell Processing revenue guidance to $93.0M–$94.0M and total revenue guidance (post-evo sale) to $95.0M–$96.0M. The company completed the sale of its evo cold chain business for $25.5M in early October 2025.
BioLife Solutions (NASDAQ: BLFS) will release its third quarter 2025 financial results after market close on Thursday, November 6, 2025. Management will host a conference call and live webcast the same day at 4:30 PM ET (1:30 PM PT) to present an overview of financial results and a general business update.
Investors can access the live webcast at the company Investor Relations page and join the call via toll-free 1-833-630-0431 or international 1-412-317-1808. A replay will be available about two hours after the call and archived on the investor site for 90 days.
BioLife Solutions (Nasdaq: BLFS) announced the sale of its wholly owned cold chain logistics subsidiary, SAVSU Cleo Technologies (f/k/a SAVSU Technologies), to Peli BioThermal for $25.5 million in cash, subject to customary adjustments.
The company said the divestiture will streamline its product portfolio and operations to concentrate resources on high-margin recurring revenue in its core cell and gene therapy tools and services business.
BioLife Solutions (Nasdaq: BLFS) reported strong Q2 2025 financial results with total revenue of $25.4 million, up 29% year-over-year. Cell Processing revenue reached $23.0 million, increasing 28% from Q2 2024. The company achieved a GAAP gross margin of 62% and adjusted EBITDA of $6.1 million (24% of revenue).
Despite reporting a GAAP net loss of $15.8 million, largely due to a one-time $15.5 million IPR&D expense from the PanTHERA acquisition, BioLife raised its 2025 revenue guidance to $100.0-103.0 million. The company's biopreservation media is now embedded in 16 approved therapies and supports over 250 clinical trials, including 30+ in Phase III.
[ "Cell Processing revenue grew 28% year-over-year to $23.0 million", "Strong adjusted EBITDA of $6.1 million, representing 24% of revenue", "Raised full-year 2025 revenue guidance to $100.0-103.0 million", "Biopreservation media embedded in 16 approved therapies", "70% market share in commercially sponsored clinical trials", "Healthy cash position of $100.2 million as of June 30, 2025" ]BioLife Solutions (NASDAQ: BLFS), a leading bioproduction products supplier for cell and gene therapy, has made a $2 million strategic investment in Pluristyx through convertible notes. The investment includes a board observer seat and potential future acquisition rights.
Pluristyx, a Seattle-based company, develops innovative induced pluripotent stem cell (iPSC) products for cell therapy developers. The investment aligns with BioLife's strategy of exploring biological assays as a product portfolio expansion, following similar investments in Sexton and PanTHERA.
BioLife Solutions (NASDAQ: BLFS), a leading developer and supplier of bioproduction products and services for the cell and gene therapy market, will release its second quarter 2025 financial results after market close on Thursday, August 7, 2025.
The company will host a conference call and webcast at 4:30 PM ET where management will discuss financial results and provide a business update. Investors can access the webcast through BioLife's website or join via phone using the provided toll-free numbers.
BioLife Solutions (NASDAQ: BLFS), a leading developer and supplier of bioproduction products and services for the cell and gene therapy market, has announced its participation in five upcoming investor conferences in May and June 2025. The company will attend the Craig-Hallum Institutional Investor Conference (May 28, Minneapolis), Benchmark Healthcare House Call Virtual Conference (May 29), Jefferies Global Life Sciences Conference (June 3-5, New York), Wolfe Research Small & Mid-Cap Conference (June 5, New York), and Northland Growth Conference (June 25, Virtual).
FAQ
What is the current stock price of Biolife Solutions (BLFS)?
What is the market cap of Biolife Solutions (BLFS)?
